Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2025-07-31

Summary

The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).

• Phase: Phase 2

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: AstraZeneca
• Treatments: Durvalumab; Tremelimumab